Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics Presents Data from its Bexotegrast Program at The Liver Meeting® 2024
Pliant Therapeutics, Inc. (NASDAQ: PLRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $38.00 price target on the stock.
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results [Yahoo! Finance]
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results